Ixazomib (MLN-2238)
| Catalog Number | Pack Size | List Price* | Quantity | |
|---|---|---|---|---|
| F1110-5MG | 5 mg | 137,00 | Add | |
| F1111-25MG | 25 mg | 445,00 | Add |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Please inquire a quote for two or more UBPBio products
Ixazomib (MLN2238) (commercial name: Ninlaro®) is the first and only FDA-approved oral proteasome inhibitor for the treatment of multiple myeloma. It reversibly inhibits the chymotrypsin-like activity of proteasomes with IC50 of 3.4 nM in cell-free assays, also inhibits the caspase-like and trypsin-like activities of proteasome with IC50 of 31 and 3500 nM, respectively.
| Category | Inhibitor |
| Supplier | UBPBio |
| Regulatory Status | RUO |
| Format | Powder; no buffer |
| CAS-Number | 1072833-77-2 |
| Storage Conditions | -20°C |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.ubpbio.com |
| Shipping Details | Ambient temp. |
| Material Safety Data Sheet | Download PDF |
